Nearly two years after reporting successful results from a phase 3 trial of its oral version of injected obesity treatment ...

Novo Nordisk filed for approval of an oral, 25-mg formulation of its weight loss blockbuster “earlier this year,” according ...

The court ruled in favor of Novo Nordisk and the FDA, rejecting a compounding pharmacy group's attempt to stop the FDA's ...

which was a significant improvement on Novo Nordisk's main marketed obesity drug – Wegovy – which is based on semaglutide alone. Novo Nordisk emphasised an interpretation of the data ...

The tortoise (Eli Lilly) has caught the hare (Novo Nordisk), according to a report from BMO Capital Markets, which cites the ...

Prescribing of drugs between 2021 and 2023 shifted dramatically for both type 2 diabetes and weight loss for people with ...

Preclinical data presented at Obesity Week in Texas, US in November 2024 suggested that combining LX9851 with Novo Nordisk’s flagship drug semaglutide, marketed as Ozempic in type 2 diabetes and ...

Novo Nordisk NVO shares have lost 16.7%, attributable to both sector-specific developments and broader macroeconomic ...